Terms: = Breast cancer AND SDC4, ENSG00000124145, 6385, P31431, SYND4, MGC22217 AND Treatment
9 results:
1. Syndecan-4 regulates the HER2-positive breast cancer cell proliferation cells via CK19/AKT signalling.
Pham SH; Vuorinen SI; Arif KT; Griffiths LR; Okolicsanyi RK; Haupt LM
Biochimie; 2023 Apr; 207():49-61. PubMed ID: 36460206
[TBL] [Abstract] [Full Text] [Related]
2. sdc4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk.
Vuorinen SI; Okolicsanyi RK; Gyimesi M; Meyjes-Brown J; Saini D; Pham SH; Griffiths LR; Haupt LM
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4563-4578. PubMed ID: 36152082
[TBL] [Abstract] [Full Text] [Related]
3. Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.
Beauvais DM; Nelson SE; Adams KM; Stueven NA; Jung O; Rapraeger AC
J Biol Chem; 2022 Jun; 298(6):102029. PubMed ID: 35569509
[TBL] [Abstract] [Full Text] [Related]
4. Syndecan-1 and -4 influence Wnt signaling and cell migration in human breast cancers.
Pham SH; Pratt K; Okolicsanyi RK; Oikari LE; Yu C; Peall IW; Arif KT; Chalmers TA; Gyimesi M; Griffiths LR; Haupt LM
Biochimie; 2022 Jul; 198():60-75. PubMed ID: 35183674
[TBL] [Abstract] [Full Text] [Related]
5. The action of hyaluronan in functional properties, morphology and expression of matrix effectors in mammary cancer cells depends on its molecular size.
Tavianatou AG; Piperigkou Z; Koutsakis C; Barbera C; Beninatto R; Franchi M; Karamanos NK
FEBS J; 2021 Jul; 288(14):4291-4310. PubMed ID: 33512780
[TBL] [Abstract] [Full Text] [Related]
6. Association of heparan sulfate proteoglycans SDC1 and sdc4 polymorphisms with breast cancer in an Australian Caucasian population.
Okolicsanyi RK; Buffiere A; Jacinto JM; Chacon-Cortes D; Chambers SK; Youl PH; Haupt LM; Griffiths LR
Tumour Biol; 2015 Mar; 36(3):1731-8. PubMed ID: 25361632
[TBL] [Abstract] [Full Text] [Related]
7. Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells.
Ridgway LD; Wetzel MD; Ngo JA; Erdreich-Epstein A; Marchetti D
Mol Cancer Res; 2012 Jun; 10(6):689-702. PubMed ID: 22513363
[TBL] [Abstract] [Full Text] [Related]
8. Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors.
Torrisi R; Dellapasqua S; Ghisini R; Viale G; Veronesi P; Luini A; Intra M; Peruzzotti G; Rocca A; Balduzzi A; Cardillo A; Goldhirsch A; Colleoni M
Breast; 2008 Dec; 17(6):654-60. PubMed ID: 18595702
[TBL] [Abstract] [Full Text] [Related]
9. Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer.
Helle SI; Geisler J; Anker GB; Leirvaag B; Holly JM; Lønning PE
Br J Cancer; 2001 Jul; 85(2):147-51. PubMed ID: 11461068
[TBL] [Abstract] [Full Text] [Related]
